Stocks to Buy in January 2026. Part I.

Schwab U.S. REIT ETF (SCHH)

Current price: 21.00

No price targets on this. Meant to be a position that provides steady dividend income. This is an income generating asset so total return is often driven more by dividends than price appreciation.

Investors looking for a simple, low-cost way to gain diversified exposure to real estate may find Schwab U.S. REIT ETF(SCHH) to be a strong fit. The fund tracks an index of roughly 120 publicly traded equity REITs across sectors like residential, industrial, retail, healthcare, and data centers. It’s rebalanced quarterly, helping maintain diversification while keeping costs extremely low, making it a solid long-term core holding for real estate exposure. $SCHH holds REITs across:

• Apartments & residential
• Industrial warehouses
• Retail & shopping centers
• Data centers
• Healthcare & storage
• Office

Why REITs for 2026 and beyond?

The macro backdrop is starting to turn more favorable for REITs. As interest rates trend lower, financing costs decline, property values typically stabilize or rise, and dividend yields become more attractive relative to bonds. Lower rates also improve REIT cash flows, giving operators more flexibility to refinance debt, fund acquisitions, and support dividend growth.

At the same time, several REIT sub-sectors are supported by long term demand drivers, including logistics and warehouses tied to e-commerce, data centers driven by AI and cloud growth, and residential properties supported by housing shortages. Combined with attractive income potential and historically strong performance during easing rate cycles, REITs are well positioned to play both an income and diversification role in portfolios heading into 2026+.

Edwards LifeSciences (EW)

Entry: Unlock

Price target: 94.00-95.00

Second PT: Unlock

Edwards Lifesciences is trading near its yearly highs following FDA approval of its SAPIEN M3 system, a minimally invasive treatment for patients with moderate to severe mitral valve leakage who are not candidates for open-heart surgery or existing catheter-based repair options.

While the underlying science may be complex, the importance of this approval is clear. Mitral regurgitation can significantly reduce quality of life and, in severe cases, become life-threatening. The approval of SAPIEN M3 represents a meaningful breakthrough in structural heart care, expanding Edwards’ transcatheter portfolio and enabling a less invasive mitral valve replacement option that reduces valve leakage, improves symptoms, and enhances overall patient outcomes.

Beyond this approval, Edwards is already a well established leader in the cardiovascular space, with a strong focus on structural heart disease and alternatives to open-heart surgery. The company has generated billions of dollars from its heart valve and transcatheter therapies, and recent performance highlights continued momentum. Revenue grew 12% and 14.7% in each of the last two quarters, while free cash flow surged 72%, underscoring both demand strength and improving operating leverage. While the stock is trading near consensus analyst price targets, the combination of new product approvals and rising demand for minimally invasive cardiac procedures could allow Edwards to capture a larger share of the structural heart market over time.

Acquisitions & expansion

Edwards LifeSciences has also been growing through acquisitions. Deals like Endotronix and the planned JenaValve (if approved) acquisition help expand its reach into heart failure monitoring and harder to treat valve conditions. 

Risks

That said, there are still risks. The stock is already trading near its annual highs so a lot of the good news could be priced in. $EW could be priced for perfection so they must continue performing well and post strong guidance on their coming earnings to keep investors’ attention. 

Please note that price targets are subject to change based on market developments and company updates. These stocks usually take time to come around. We'll be updating the stock as needed for our Hyper Stocks Pro members. Wanna see real-time market updates? Learn more here.

Lockheed Martin (LMT)

Entry: 475.00-485.00

Price target: Unlock

Second PT: Unlock

Global defense spending is experiencing significant growth, with recent projections showing compound annual growth rates (GAGRs) ranging from 4.9% to over 8% for the mid 2020s, driven by geopolitical tensions and military modernizations. Estimates show that total spending last year was near $2.7 trillion and is projected to rise towards $6 trillion by 2035.

Whether you agree with defense spending or not, we live in a world where threats are real and defense systems must continue advancing for us to maintain our freedom. Lockheed Martin is the world’s largest defense contractor, providing the U.S. and its allies with combat aircraft like the F-35 fighter jet, missiles and precision strike weapons. Helicopters (including the infamous Black Hawk), radar systems, and space systems and satellites. 

It’s safe to say that the company provides a lot of critical products and systems to the world, making them a strong name to watch as global defense spending increases in the coming decade. 

Wars ending is a good thing, there’s no argument there, but even if wars ended, Lockheed Martin still has a backlog that shows a record of more than $176 billion, demonstrating strong future demand. NATO allies and the Middle East are ramping up arms purchases to upgrade their arsenal, likely to protect from further Russian advances (specifically for NATO). The company just secured the largest Patriot missile contract in history, awarded by the U.S. Army. And another $10.85B contract from the U.S. Marine Corps. This shows that they’re seeing demand on the home front and across the globe 

Financials:

The stock has been relatively flat over the last three years, and rightfully so. LMT’s revenue has been flat while peers like RTX and NOC were growing sales. However LMT’s revenue has shown signs of recovery this year, with last quarter growing 8.8%. A recent guidance / outlook increase on both revenue and earnings is another promising signals. 

LMT’s outlook and backlog suggest that there’s a good chance it’s about ready to breakout from its three year consolidation and finally move back into a “rally” stage. Trump’s big push on defense and the globe’s increased spending could be a catalyst for the defense sector as a whole, but LMT must continue landing big contracts and increasing revenue to maintain investor attention over its competitors.

Please note that price targets are subject to change based on market developments and company updates. These stocks usually take time to come around. We'll be updating the stock as needed for our Hyper Stocks Pro members. Wanna see real-time market updates? Learn more here.

Stock Name - Unlock

Entry: 17.50-18.50

Price target: 21.50-23.50

Second PT: 25.00+

You've reached the end of our complimentary public watchlist. Unlock for the full list by becoming a member of our Hyper Stocks community. Click here to unlock more high probability set-ups!

Stock Name - Unlock

Entry: 53.00-55.00

Price target: 62.00-64.00

Second PT: 68.00+

You've reached the end of our complimentary public watchlist. Unlock for the full list by becoming a member of our Hyper Stocks community. Click here to unlock more high probability set-ups!

Stock Name - Unlock

Entry: 140.00-141.00 

Price target: 180.00-185.00

Second PT: TBD

You've reached the end of our complimentary public watchlist. Unlock for the full list by becoming a member of our Hyper Stocks community. Click here to unlock more high probability set-ups!

Stock Name - Unlock

Entry: 20.00-21.00

Price target: 23.00-24.00

Second PT: 25.00-26.00

You've reached the end of our complimentary public watchlist. Unlock for the full list by becoming a member of our Hyper Stocks community. Click here to unlock more high probability set-ups!